We summarise the key findings of a research paper co-authored by a pharmaceutical data provider. Using Takeda Pharmaceutical’s FY 2017 Q4 pipeline as an example, we also provide a brief overview of how phase transition data can be used by investors to gain a better understanding of which drugs are most likely to be approved by the FDA and to analyse the health of a pharmaceutical company’s pipeline.
This research paper analyses individual drug program phase transitions over a ten year period in order to determine FDA approval success rates for investigational drugs. Research is conducted using data sourced from the pharmaceutical data provider shown below that tracks and analyses
Find out more about Neudata and keep up-to-date by signing up to our email newsletter.